title: [Five-year results of IMRT for prostate cancer - toxicity].
abstract: BACKGROUND
  Intensity modulated radiotherapy (IMRT) plays a crucial role in the treatment of prostate cancer thanks to its capacity for healthy tissue sparing. This work reports on the acute and late toxicity rates among 233 patients treated with high-dose IMRT.
  
  
  METHODS
  From June 2003 to December 2007, 233 men with clinically localized prostate cancer underwent radical radiotherapy. One hundred sixty patients were treated with IMRT to the prostate and the base of seminal vesicles to 78 Gy in 39 fractions, 73 patients underwent simultaneous integrated boost. Prescribed doses were 82 Gy and 73,8 Gy in 41 fractions to the prostate and seminal vesicles, respectively. Late toxicity was evaluated prospectively using a RTOG/FC-LENT score.
  
  
  RESULTS
  Thirty patients (12.8%) experienced acute Grade 2 gastrointestinal (GI) toxicity. No acute Grade 3 or 4 GI toxicity developed. Forty two patients (18.1%) experienced acute Grade 2 genitourinary toxicity and 23 patients (9.9%) had Grade 3 GU toxicity. Grade 4 Genitourinary toxicity was observed in nine (3.8%) patients, due to a need of short-term urinary catheterization. With a median follow-up of 49.2 months, the estimated 5-year cumulative incidence of Grade 2 gastrointestinal toxicity was 22.4%. The estimated 5-year cumulative incidence of Grade 2 genitourinary toxicity was 17.7%.
  
  
  CONCLUSIONS
  Intensity modulated radiotherapy enables dose escalation to 78-82 Gy with an acceptable toxicity.
authors: M
authors: M
authors: Doležel
authors: K
authors: K
authors: Odrážka
authors: J
authors: J
authors: Vaňásek
authors: M
authors: M
authors: Vaculíková
authors: J
authors: J
authors: Šefrová
authors: J
authors: J
authors: Jansa
authors: Z
authors: Z
authors: Mačingová
authors: M
authors: M
authors: Zouhar
authors: P
authors: P
authors: Paluska
authors: M
authors: M
authors: Broďák
authors: I
authors: I
authors: Hartmann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002404:Catheterization / Q000379:methods; D004064:Digestive System / Q000528:radiation effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects* / Q000379:methods*; D014566:Urogenital System / Q000528:radiation effects